In fact, it has been shown that MS patients have significantly lower serum levels of IFN-γ, IL-10, and IFN-γ/IL-10 ratio than patients with either noninflammatory or inflammatory neurological disorders (53, 54), whereas IL-2 and IFN-γ were reported as good biomarkers in discriminating MS from neuromyelitis optica (NMO) (54). This evidence concerns the gene IL2 and myeloid sarcoma.